Is Dendreon a Turnaround Candidate?

In less than a year and a half, Dendreon (Nasdaq: DNDN  ) has gone from blockbuster potential to potential turnaround candidate in the wake of a slower-than-expected start for the launch of its prostate cancer treatment Provenge.

Last week, the company announced layoffs, as expected, to lower the cash burn rate. Provenge is produced specifically for each patient, so if Dendreon is selling less than expected, there's manufacturing personnel sitting on their hands with nothing to do. Dendreon is also cutting administrative jobs. Basically, anything that doesn't increase sales directly was affected. All told, it's a 25% reduction in head count.

The company is changing its strategy in Europe. Rather than using a contract manufacturer and then transferring to its own facility once it's built, the plan is now to continue using a contract manufacturer for the foreseeable future.

All told, the restructuring should result in saving $120 million annually. With the new cost structure, the biotech thinks it'll be cash-flow breakeven at $500 million in revenue. There was no word on when Dendreon thought this might happen, though management said the goal was to be cash-flow positive before the company would run out of cash and have to dilute shareholders. Again.

Dendreon is still guiding for modest quarter-over-quarter growth for the rest of the year, but the company released August sales numbers that looked pretty good to me: $22 million, or a 16% increase over July. That's only a run rate of $250 million or so -- a far cry from the $800 million it was hoping to end the year with -- but if sales continue to increase at that rate, it won't take too long to reach the magic $500 million mark.

Whether Dendreon is a good turnaround candidate is solely based on whether the company is correct that reimbursement for doctors is why prescriptions are slow, or whether there's a bigger issue. Management said doctors are being paid in about 30 days, a considerable improvement, but it may take a few rounds of timely reimbursement before they increase their prescription habits.

If reimbursement isn't the issue, then Dendreon has much bigger problems. If the market isn't as big as expected or if competition from Johnson & Johnson's (NYSE: JNJ  ) Zytiga or Sanofi's (NYSE: SNY  ) Jevtana is creeping in, cutting $120 million isn't going to solve its problem.

As with any turnaround target, only time will tell which theory is correct. Add Dendreon to the Fool's watchlist service to keep up to date with the turnaround. Don't have a My Watchlist account? Sign up here for free.

Dendreon may not be a top stock right now, but download this special free report, "The Motley Fool's Top Stock for 2011," and see which little company we reveal as a market beater.

Fool contributor Brian Orelli holds no position in any company mentioned. Click here to see his holdings and a short bio. The Motley Fool owns shares of Johnson & Johnson and Dendreon. Motley Fool newsletter services have recommended buying shares of and creating a diagonal call position in Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Read/Post Comments (1) | Recommend This Article (6)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On September 13, 2011, at 10:47 AM, bengbeng1000 wrote:

    "If reimbursement isn't the issue, then Dendreon has much bigger problems. If the market isn't as big as expected or if competition from Johnson & Johnson's (NYSE: JNJ ) Zytiga or Sanofi's (NYSE: SNY ) Jevtana is creeping in, cutting $120 million isn't going to solve its problem."

    I think you'd better to read the presentation DNDN made yesterday, Provenge should be used before Zytiga/Jevtana, they are not competitor, and DNDN will get money before those two.

    So, if you are wrong, stop misleading fools here

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 1551871, ~/Articles/ArticleHandler.aspx, 10/21/2014 9:42:22 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement